CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of January 6, 2017 by and among NOVADAQ TECHNOLOGIES INC. and NOVADAQ CORP., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and...Credit and Security Agreement (Term Loan) • January 19th, 2017 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • New York
THIS CREDIT AND SECURITY AGREEMENT (TERM LOAN) (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of January 6, 2017 by and among NOVADAQ TECHNOLOGIES INC., a corporation validly existing under the Canada Business Corporations Act (“Novadaq Tech”), NOVADAQ CORP., a Delaware corporation (“Novadaq Corp”) and any additional borrower that may hereafter be added to this Agreement (individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender.
3,900,000 Shares NOVADAQ TECHNOLOGIES INC. (incorporated under the Canada Business Corporations Act) Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2013 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • New York
Novadaq Technologies Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to sell to Canaccord Genuity Inc. (the “Underwriter”), an aggregate of 3,900,000 common shares (the “Firm Shares”) of the Company (the “Common Shares”). The Company has also granted to the Underwriter an option to purchase up to an aggregate of 585,000 additional Common Shares, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement are herein collectively called the “Securities.”
CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) dated as of January 6, 2017 by and among NOVADAQ TECHNOLOGIES INC. and NOVADAQ CORP., and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and...Credit and Security Agreement (Revolving Loan) • January 19th, 2017 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • New York
THIS CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of January 6, 2017 by and among NOVADAQ TECHNOLOGIES INC., a corporation validly existing under the Canada Business Corporations Act (“Novadaq Tech”), NOVADAQ CORP., a Delaware corporation (“Novadaq Corp”) and any additional borrower that may hereafter be added to this Agreement (individually as a “Borrower”, and collectively with any entities that become party hereto as Borrower and each of their successors and permitted assigns, the “Borrowers”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust, individually as a Lender, and as Agent, and the financial institutions or other entities from time to time parties hereto, each as a Lender.
Marketing and Sales Distribution Alliance AgreementMarketing and Sales Distribution Alliance Agreement • February 29th, 2012 • Novadaq Technologies Inc • Delaware
This Marketing and Sales Distribution Alliance Agreement (the “Agreement”) is made and entered into as of November 29, 2011 (the “Effective Date”) by and between LifeCell Corporation, a Delaware corporation, having its principal place of business at One Millennium Way, Branchburg, NJ 08876 (“LifeCell”) and Novadaq Technologies Inc., a corporation, having its headquarters at 2585 Skymark Avenue, Suite 306, Mississauga, Ontario, Canada L4W 4L5, together with its United States subsidiary Novadaq Corp. (“Novadaq”); LifeCell and Novadaq both together are referred to as the “Parties” and individually as a “Party.”
Marketing and Sales Distribution Alliance AgreementMarketing and Sales Distribution Alliance Agreement • February 29th, 2012 • Novadaq Technologies Inc • Delaware
This Marketing and Sales Distribution Alliance Agreement (the “Agreement”) is made and entered into as of November 29, 2011 (the “Effective Date”) by and between LifeCell Medical Resources Limited, a limited company organized and existing under the laws of the Republic of Ireland but resident in the Cayman Islands, with its principal place of business at Zephyr House, 122 Mary Street, P.O. Box 709, Grand Cayman, Cayman Islands (“LifeCell MR”) and Novadaq Technologies Inc., a corporation, having its headquarters at 2585 Skymark Avenue, Suite 306, Mississauga, Ontario, Canada L4W 4L5, together with its United States subsidiary Novadaq Corp. (“Novadaq”); LifeCell MR and Novadaq both together are referred to as the “Parties” and individually as a “Party.”
Marketing and Sales Distribution Alliance AgreementMarketing and Sales Distribution Alliance Agreement • February 29th, 2012 • Novadaq Technologies Inc • Delaware
This Marketing and Sales Distribution Alliance Agreement (the “Agreement”) is made and entered into as of November 29, 2011 (the “Effective Date”) by and between KCI USA, Inc., a Delaware corporation, with offices at 8023 Vantage Drive, San Antonio, TX 78230 (“KCI US”) and Novadaq Technologies Inc., a corporation, having its headquarters at 2585 Skymark Avenue, Suite 306, Mississauga, Ontario, Canada L4W 4L5, together with its United States subsidiary Novadaq Corp. (“Novadaq”); KCI US and Novadaq both together are referred to as the “Parties” and individually as a “Party.”
DISTRIBUTION AGREEMENTDistribution Agreement • February 29th, 2012 • Novadaq Technologies Inc • New Jersey
This Distribution Agreement (this “Agreement”) is made on November 10, 2011 (the “Agreement Date”) to take effect on January 1, 2012 (the “Effective Date”), by and between Novadaq Technologies, Inc., together with its US subsidiary, Novadaq Corp., having a place of business at 2585 Skymark Avenue, Suite 306, Mississauga, ON L4W 4L5, CANADA (“Novadaq”), and Maquet Cardiovascular LLC, having a place of business at 45 Barbour Pond Dr., Wayne, NJ 07470 (“Distributor”).
NOVADAQ TECHNOLOGIES INC. AND STRYKER CANADA OPERATIONS ULC AND STRYKER CORPORATIONArrangement Agreement • June 20th, 2017 • Novadaq Technologies Inc • Electromedical & electrotherapeutic apparatus • Ontario
STRYKER CORPORATION, a corporation existing under the laws of Michigan with its head office in Kalamazoo, Michigan (“Stryker”)
Marketing and Sales Distribution Alliance AgreementMarketing and Sales Distribution Alliance Agreement • February 29th, 2012 • Novadaq Technologies Inc • Delaware
This Marketing and Sales Distribution Alliance Agreement (the “Agreement”) is made and entered into as of November 29, 2011 (the “Effective Date”) by and between KCI Medical Resources Ltd, a nonresident corporation organized, registered in, and existing under the laws of the Republic of Ireland, having its principal place of business at 122 Mart Street, Zephyr House, Grand Cayman, Cayman Islands (“KCI MR”) and Novadaq Technologies Inc., a corporation, having its headquarters at 2585 Skymark Avenue, Suite 306, Mississauga, Ontario, Canada L4W 4L5, together with its United States subsidiary Novadaq Corp. (“Novadaq”); KCI MR and Novadaq both together are referred to as the “Parties” and individually as a “Party.”
